Clinical Report: Assessment of the Viability of Tumor Treating Fields for Treating Brainstem Gliomas

Overview

This study evaluates the dosimetric performance of the MAXPOINT® system for delivering Tumor Treating Fields (TTFields) in patients with brainstem gliomas. Patient-specific array configurations were assessed for their ability to achieve therapeutic electric field intensities in this tumor location.

Background

Tumor Treating Fields (TTFields) have been established as a standard therapy for newly diagnosed supratentorial glioblastoma, improving survival outcomes. Brainstem gliomas present unique challenges due to their location and limited treatment options. This study aims to explore the feasibility of applying TTFields to brainstem gliomas using advanced planning technology.

Data Highlights

No numerical data or trial results are provided in the source material.

Key Findings

• TTFields disrupt mitosis and inhibit tumor growth through dielectrophoretic effects.
• The MAXPOINT® system allows for individualized treatment planning for infratentorial tumors, including brainstem gliomas.
• Local minimum field intensity (LMiFI) and local minimum power density (LMiPD) were characterized within the target volume.
• The study included simulations based on data from seven patients with brainstem gliomas treated between 2022 and 2024.
• Prior studies suggested theoretical feasibility of TTFields in brainstem gliomas but did not establish practical application.

Clinical Implications

Further clinical studies are necessary to validate these findings and assess the therapeutic benefits in this patient population.

Conclusion

The study demonstrates the potential for achieving therapeutic electric field intensities in brainstem gliomas using patient-specific TTFields configurations.

Related Resources & Content

1. Frontiers in Neurology, 2026 -- Efficacy of tumor treating fields in high-grade glioma: a real-world retrospective analysis of 28 patients
2. The ASCO Post, 2017 -- ‘Out-of-the-Box’ Approach Plus Temozolomide Extends Survival in Glioblastoma
3. Journal of Neuro-Oncology, 2024 -- Targeting glioblastoma networks using tumor treating fields (TTFields) in laboratory models
4. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial - PMC
5. Journal of Neuro-Oncology — Intratumoral modulation therapy using low-intensity electric fields shows effectiveness against diffuse intrinsic pontine glioma cells
6. Tumor Treating Fields (TTFields) for Brain Tumors in Adults | American Cancer Society
7. Study Details | NCT05310448 | Tumor Treating Fields for the Treatment of Brainstem Gliomas | ClinicalTrials.gov
8. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial - PMC
9. Optune Gio® | FDA-approved glioblastoma (GBM) treatment
10. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline | Journal of Clinical Oncology
11. The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1 - PMC
12. What is Optune Gio? | Optune Gio HCP
13. Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma - PMC
14. Checking your browser - reCAPTCHA